A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
The purpose of this study is to examine the effects of a new medication (DN24-02) when used to treat those who just had surgery to treat their urothelial cancer (that expresses HER2/neu)
Males and Females, 18 and older, with urotherlial cancer that expresses HER2/neu.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Subjects will be followed for life.
Community Oncology 503.601.7641